STOCK TITAN

Aspira (NASDAQ: AWHL) director boosts stake and updates large warrant holdings

(Neutral)
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Aspira Women's Health director Fraser John D filed an amended Form 4 to correct the number of shares indirectly held through Seamark Capital and the presentation of his warrant holdings as of September 17, 2025. He bought 16,389 shares of common stock at $0.45 per share and acquired a warrant for 12,292 underlying shares with a $0.75 exercise price. Following these transactions, he directly owns 566,393 common shares and holds 287,769 shares indirectly via Seamark Capital. He also holds warrants covering 900,633 shares at a $0.35 exercise price expiring in 2031 and 68,627 shares at a $2.25 exercise price expiring in 2027, plus the new warrant for 12,292 shares expiring in 2030.

Positive

  • None.

Negative

  • None.
Insider Fraser John D
Role Director
Bought 28,681 shs ($7K)
Type Security Shares Price Value
Purchase Warrant (Right to Buy) 12,292 $0.00 $0.00
Purchase Common Stock 16,389 $0.45 $7K
holding Warrant (Right to Buy) -- -- --
holding Warrant (Right to Buy) -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Warrant (Right to Buy) — 981,552 shares (Direct); Common Stock — 566,393 shares (Direct); Common Stock — 287,769 shares (Indirect, By Seamark Capital)
Footnotes (1)
  1. F1. This report is being filed to correct the number of shares indirectly held by Mr. Fraser on September 17, 2025 and the presentation of the warrants held on September 17, 2025.
Common shares purchased 16,389 shares at $0.45 Open-market purchase on September 17, 2025
New warrant acquired 12,292 underlying shares, $0.75 exercise Derivative purchase on September 17, 2025; expires 2030
Direct common shares after transaction 566,393 shares Direct ownership following September 17, 2025 trades
Indirect common shares 287,769 shares Indirectly held via Seamark Capital as of September 17, 2025
Large warrant position 1 900,633 shares at $0.35 Warrant expiring March 5, 2031
Large warrant position 2 68,627 shares at $2.25 Warrant expiring July 9, 2027
Net buy shares equivalent 28,681 shares Net of reported buy/sell activity in transaction summary
Warrant (Right to Buy) financial
"security_title: "Warrant (Right to Buy)" with underlying common stock details"
open-market purchase financial
"transaction_action: "open-market purchase" for code P transactions"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
indirectly held financial
"correct the number of shares indirectly held by Mr. Fraser"
exercise price financial
"conversion_or_exercise_price fields such as "0.3500" and "2.2500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Form 4/A regulatory
"amended Form 4 ownership report context in the insider filing data"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does the latest Form 4/A for Aspira Women's Health (AWHL) show?

The Form 4/A shows that director Fraser John D corrected prior ownership details and reported new open-market purchases. He bought 16,389 common shares at $0.45 and a warrant covering 12,292 shares with a $0.75 exercise price on September 17, 2025.

How many Aspira Women's Health (AWHL) shares does Fraser John D now hold?

After the reported transactions, he directly owns 566,393 common shares and indirectly holds 287,769 shares through Seamark Capital. These holdings reflect corrected ownership figures as of September 17, 2025, combining both direct and indirect positions disclosed in the amended filing.

Was the Aspira Women's Health (AWHL) Form 4/A mainly a correction?

Yes. A footnote states the report corrects the indirectly held share count for Fraser on September 17, 2025 and the presentation of his warrants on that date. It updates, rather than newly creating, his previously reported ownership information.

Did Fraser John D buy or sell Aspira Women's Health (AWHL) stock in this Form 4/A?

The filing reports net buying activity. He made open-market purchases of 16,389 common shares at $0.45 and acquired a warrant for 12,292 underlying shares. The transaction summary shows a total net buy of 28,681 shares equivalent.

How significant are the derivative positions reported for Aspira Women's Health (AWHL)?

The filing lists sizable warrant positions: 900,633 underlying shares at $0.35 expiring in 2031 and 68,627 shares at $2.25 expiring in 2027. Together with the new 12,292-share warrant, they represent substantial potential future share acquisitions.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fraser John D

(Last)(First)(Middle)
C/O ASPIRA WOMEN'S HEALTH INC
12117 BEE CAVES RD, BLDG 3-100

(Street)
AUSTIN TEXAS 78738

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aspira Women's Health Inc. [ AWHL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
09/19/2025
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/17/2025P16,389A$0.45566,393D
Common Stock287,769(1)IBy Seamark Capital
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrant (Right to Buy)$0.7509/17/2025P12,29209/17/202509/17/2030Common Stock, par value $0.00112,292$012,292(1)D
Warrant (Right to Buy)$2.2507/09/202407/09/2027Common Stock, par value $0.00168,62768,627D
Warrant (Right to Buy)$0.3509/12/202503/05/2031Common Stock, par value $0.001900,633900,633D
Explanation of Responses:
1. This report is being filed to correct the number of shares indirectly held by Mr. Fraser on September 17, 2025 and the presentation of the warrants held on September 17, 2025.
/s/ John D. Fraser05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)